Proteomic Cancer Data Analysis for BioCrypton

Argentys enters into a strategic collaboration with BioCrypton to provide comprehensive Big Data proteomics analysis in support of BioCrypton’s biomarker discovery programs. BioCrypton is a personalized medicine start-up that leverages its innovative glycomic technology to develop the new generation of molecular information assays and biochip clinical tests for oncology and other complex chronic diseases with high unmet medical need. Argentys is an innovative service partner with the expertise in the large scale biomedical data analytics delivering actionable answers from laboratory and clinical data.